Corvus Pharmaceuticals initiates second arm of CPI-006 study

Corvus Pharmaceutical announced that it has initiated patient enrollment in the second arm of its ongoing Phase 1/1b dose-escalation study. This arm is evaluating CPI-006, a humanized monoclonal antibody directed against CD73, in combination with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor. The Phase 1/1b study is currently enrolling patients with non-small cell lung cancer, renal cell carcinoma and other cancers who have failed standard therapies. The first arm of the study is evaluating CPI-006 as a single agent and has dosed patients in several cohorts of escalating doses. A third arm is planned to evaluate CPI-006 in combination with pembrolizumab, an anti-PD-1 antibody.
https://thefly.com/landingPageNews.php?id=2845491